tambaku Risperdal is prescribed for the treatment of schizophrenia and bipolar disorders and has been used in off-label capacities to treat behavioral disorders such as dementia, ADHD, depression, anxiety and autism. Approved in 1993, sales of Risperdal peaked in 2007 at more than $4.5 billion.

New research has recently surfaced supporting allegations that Risperdal may cause the development of breasts in young males, a condition known as Gynecomastia.

A study published in a 2006 issue of the Journal of Clinical Psychopharmacology stated that risperidone, the generic form of Risperdal, administered to adolescents at doses commonly used for the treatment of psychotic symptoms can strongly increase prolactin levels, with clinical consequences such as gynecomastia.

In recent months, Johnson & Johnson, the manufacturer of Risperdal, has lost three consecutive class action lawsuits over their marketing tactics of the drug and In September 2012, the company settled an individual Risperdal lawsuit filed on behalf of a young man who developed female breasts after being treated with the drug for a period of five years.

A number of pending lawsuits filed on behalf of adolescent men and boys allege that Risperdal caused them to grow female breasts. Johnson & Johnson has already settled a number of these cases out of court with confidential payouts.

If you or a loved one took Risperdal and were diagnosed with:

  • Gynecomastia – a condition in which males develop female breasts
You may be entitled to significant compensation from the manufacturer.

Contact National Information Systems today to speak with an experienced attorney to determine if you may qualify. There are time deadlines to file a claim so don’t wait — act now.

Fields marked with a * are required.


Connect immediately with a
National Information Systems attorney